KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Account Payables: 2020-2025

Historic Change in Account Payables for Aquestive Therapeutics (AQST) over the last 6 years, with Sep 2025 value amounting to -$1.3 million.

  • Aquestive Therapeutics' Change in Account Payables fell 169.62% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 415.84%. This contributed to the annual value of $2.8 million for FY2024, which is 372.75% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Change in Account Payables stood at -$1.3 million, which was down 304.33% from -$323,000 recorded in Q2 2025.
  • Aquestive Therapeutics' Change in Account Payables' 5-year high stood at $2.6 million during Q4 2024, with a 5-year trough of -$3.0 million in Q2 2024.
  • For the 3-year period, Aquestive Therapeutics' Change in Account Payables averaged around $185,273, with its median value being -$323,000 (2025).
  • In the last 5 years, Aquestive Therapeutics' Change in Account Payables plummeted by 1,047.24% in 2021 and then skyrocketed by 1,270.33% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Change in Account Payables (Quarterly) stood at $2.1 million in 2021, then plummeted by 153.60% to -$1.1 million in 2022, then increased by 5.07% to -$1.1 million in 2023, then spiked by 346.82% to $2.6 million in 2024, then slumped by 169.62% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$323,000 for Q2 2025, and $1.9 million during Q1 2025.